Cybin Inc News

EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program

BenzingaOct 24 19:01

Cybin Inc. CEO to Speak at Research Event

TipRanksOct 3 20:12

Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

BusinesswireSep 24 19:30

Strong Buy Rating for Cybin Inc. on Promising Clinical Advances and Strategic Management Positioning

TipRanksSep 24 16:15 · Ratings

Cybin Announces Completion of Previously Announced Share Consolidation

BusinesswireSep 19 19:26

Cybin Inc. Shareholders Approve Key Decisions

TipRanksAug 28 07:37

Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder

BusinesswireAug 13 19:30

Cybin Inc. Advances Neuropsychiatric Drug Development

TipRanksAug 8 20:23

Press Release: Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Dow JonesAug 8 19:36

Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference

BusinesswireAug 7 19:30

Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development

BenzingaJun 27 00:14